This is a transformative label expansion for AUVELITY into a large, underserved market with no FDA-approved competition for Alzheimer's agitation. Watch for the company's commercial launch execution and prescription trends over the next 2-4 quarters. The conference call on May 1 may provide revenue guidance or launch expectations.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $206.53entry
- T+1 · 7mo ago +8.31%α +8.65% · $223.70
- T+5 · 6mo ago +6.63%α +4.28% · $220.22
- T+20 · 6mo ago +11.48%α +6.20% · $230.25
- T+60 · 4mo ago +13.40%α +10.33% · $234.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment for a condition affecting up to 76% of Alzheimer's patients. This is a major label expansion for an already-approved drug (MDD), supported by Breakthrough Therapy designation and Priority Review, with a patent estate extending to at least 2043.
Key Facts
- FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026.
- AUVELITY is a first-in-class treatment targeting NMDA and sigma-1 receptors for this indication.
- The sNDA was granted Breakthrough Therapy designation and evaluated under Priority Review.
- Approval supported by Phase 3 ADVANCE-1 and ACCORD-2 trials showing statistically significant improvement on primary and key secondary endpoints.
- AUVELITY is already FDA-approved for major depressive disorder (approved 2022) and has been administered to over 300,000 patients.
- Patent estate extends to at least 2043.
- Alzheimer's disease affects more than 7 million Americans; agitation reported in up to 76% of patients.
Financial Impact
No specific financial figures provided in the filing. The approval opens a large addressable market (up to ~5.3M Alzheimer's patients with agitation) for an existing commercial product.
Risk Factors
- Commercial adoption may be slower than expected due to the elderly patient population and caregiver-driven prescribing dynamics.
- Payer coverage and reimbursement for the new indication are not yet established.
- AUVELITY carries a boxed warning for suicidal thoughts and behaviors, which may limit use in some patients.
- Competition from off-label antipsychotics and other emerging therapies could limit market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-197857 |
| Document: axsm-20260430.htm | 0001193125-26-197857 |
| Document: 0001193125-26-197857-index-headers.html | 0001193125-26-197857 |
| Document: 0001193125-26-197857-index.html | 0001193125-26-197857 |
| Document: 0001193125-26-197857.txt | 0001193125-26-197857 |
Track record
26 reports on AXSM
5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers